PRO: Patients With Hepatitis C Virus With Pretreatment Metavir Stage 3 Fibrosis Do Not Require Hepatocellular Carcinoma Surveillance After Sustained Virological Response
Amoah Yeboah‐Korang, Nicole M. Gentile, Claus J. Fimmel – 14 December 2018
Rationing Care: Barriers to Direct‐Acting Antiviral Treatment in Medicaid Treatment Criteria
Phil Waters, Tina Broder – 14 December 2018
Hepatitis C Virus in the Modern Direct‐Acting Antiviral Era: Where Have All the Special Populations Gone?
Christian B. Ramers, Stacey B. Trooskin – 14 December 2018
Targeting Transforming Growth Factor Beta Signaling in Liver Cancer
Shuyun Rao, Lopa Mishra – 14 December 2018
Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection
Jordan J. Feld, Norah A. Terrault, Hsing‐Hua S. Lin, Steven H. Belle, Raymond T. Chung, Naoky Tsai, Mandana Khalili, Robert Perrillo, Stewart L. Cooper, Marc G. Ghany, Harry L.A. Janssen, Anna S. Lok, for the Hepatitis B Research Network – 14 December 2018 – Monotherapy with interferon or nucleoside analog is generally not recommended during the immune‐tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase.
Recurrence of Hereditary Hemorrhagic Telangiectasia After Liver Transplantation: Clinical Implications and Physiopathological Insights
Jérôme Dumortier, Sophie Dupuis‐Girod, Pierre‐Jean Valette, Alexander Valent, Olivier Guillaud, Jean‐Christophe Saurin, Valérie Hervieu, Philip Robinson, Henri Plauchu, Pierre Paliard, Olivier Boillot, Jean‐Yves Scoazec – 14 December 2018 – Liver transplantation (LT) has been proposed as a curative treatment in hereditary hemorrhagic telangiectasia (HHT) with severe hepatic involvement. We provide a long‐term evaluation of graft status after LT for HHT, with a focus on the risk of recurrence.
Sofosbuvir and Ribavirin Eradication of Refractory Hepatitis E in an Immunosuppressed Kidney Transplant Recipient
Mary Drinane, Xiao Jing Wang, Kymberly Watt – 14 December 2018
Impact of Prior Bariatric Surgery on Perioperative Liver Transplant Outcomes
Baris D. Yildiz – 14 December 2018
Alpha‐Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes
Neil Mehta, Jennifer L. Dodge, John P. Roberts, Ryutaro Hirose, Francis Y. Yao – 13 December 2018 – High alpha‐fetoprotein (AFP) > 1,000 ng/mL is associated with poor outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). A new national policy has been implemented for AFP > 1,000 ng/mL requiring a decrease to < 500 ng/mL before LT, but there is a paucity of data on the optimal AFP threshold before LT.